annual EBIT:
$575.23M+$208.14M(+56.70%)Summary
- As of today (June 22, 2025), HALO annual earnings before interest & taxes is $575.23 million, with the most recent change of +$208.14 million (+56.70%) on December 31, 2024.
- During the last 3 years, HALO annual EBIT has risen by +$319.18 million (+124.66%).
- HALO annual EBIT is now at all-time high.
Performance
HALO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$148.35M-$34.40M(-18.82%)Summary
- As of today (June 22, 2025), HALO quarterly earnings before interest & taxes is $148.35 million, with the most recent change of -$34.40 million (-18.82%) on March 31, 2025.
- Over the past year, HALO quarterly EBIT has increased by +$47.82 million (+47.56%).
- HALO quarterly EBIT is now -18.82% below its all-time high of $182.75 million, reached on December 31, 2024.
Performance
HALO quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
$623.04M+$47.82M(+8.31%)Summary
- As of today (June 22, 2025), HALO TTM earnings before interest & taxes is $623.04 million, with the most recent change of +$47.82 million (+8.31%) on March 31, 2025.
- Over the past year, HALO TTM EBIT has increased by +$212.20 million (+51.65%).
- HALO TTM EBIT is now at all-time high.
Performance
HALO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
HALO EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +56.7% | +47.6% | +51.6% |
| 3 y3 years | +124.7% | +94.8% | +106.2% |
| 5 y5 years | +1048.8% | +10000.0% | +1038.5% |
HALO EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +124.7% | -18.8% | +348.0% | at high | +157.4% |
| 5 y | 5-year | at high | +1048.8% | -18.8% | >+9999.0% | at high | +1038.5% |
| alltime | all time | at high | +802.5% | -18.8% | +582.8% | at high | +743.0% |
HALO EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $148.35M(-18.8%) | $623.04M(+8.3%) |
| Dec 2024 | $575.23M(+56.7%) | $182.75M(+7.7%) | $575.23M(+15.3%) |
| Sep 2024 | - | $169.67M(+38.8%) | $498.87M(+14.6%) |
| Jun 2024 | - | $122.27M(+21.6%) | $435.46M(+6.0%) |
| Mar 2024 | - | $100.53M(-5.5%) | $410.85M(+11.9%) |
| Dec 2023 | $367.09M(+38.1%) | $106.39M(+0.1%) | $367.09M(+9.2%) |
| Sep 2023 | - | $106.27M(+8.8%) | $336.06M(+8.1%) |
| Jun 2023 | - | $97.65M(+72.0%) | $311.01M(+26.2%) |
| Mar 2023 | - | $56.78M(-24.7%) | $246.48M(-7.3%) |
| Dec 2022 | $265.87M(+3.8%) | $75.36M(-7.2%) | $265.87M(+7.5%) |
| Sep 2022 | - | $81.22M(+145.3%) | $247.37M(+2.2%) |
| Jun 2022 | - | $33.12M(-56.5%) | $242.01M(-19.9%) |
| Mar 2022 | - | $76.17M(+33.9%) | $302.16M(+18.0%) |
| Dec 2021 | $256.04M(+71.1%) | $56.87M(-25.0%) | $256.04M(-7.7%) |
| Sep 2021 | - | $75.86M(-18.7%) | $277.46M(+14.2%) |
| Jun 2021 | - | $93.27M(+210.4%) | $242.86M(+34.6%) |
| Mar 2021 | - | $30.05M(-61.6%) | $180.47M(+20.6%) |
| Dec 2020 | $149.68M(-346.9%) | $78.28M(+89.7%) | $149.68M(+268.1%) |
| Sep 2020 | - | $41.26M(+33.6%) | $40.67M(-272.9%) |
| Jun 2020 | - | $30.88M(-4250.4%) | -$23.52M(-64.6%) |
| Mar 2020 | - | -$744.00K(-97.6%) | -$66.39M(+9.5%) |
| Dec 2019 | -$60.62M(-1.8%) | -$30.73M(+34.0%) | -$60.62M(+116.9%) |
| Sep 2019 | - | -$22.92M(+91.1%) | -$27.95M(-2.2%) |
| Jun 2019 | - | -$11.99M(-338.8%) | -$28.59M(-17.6%) |
| Mar 2019 | - | $5.02M(+158.1%) | -$34.69M(-43.8%) |
| Dec 2018 | -$61.75M(-173.9%) | $1.95M(-108.3%) | -$61.75M(-197.5%) |
| Sep 2018 | - | -$23.56M(+30.3%) | $63.31M(-33.9%) |
| Jun 2018 | - | -$18.09M(-17.9%) | $95.74M(+7.8%) |
| Mar 2018 | - | -$22.04M(-117.4%) | $88.79M(+6.2%) |
| Dec 2017 | $83.59M(-202.1%) | $127.01M(+1332.4%) | $83.59M(-227.4%) |
| Sep 2017 | - | $8.87M(-135.4%) | -$65.62M(-32.3%) |
| Jun 2017 | - | -$25.04M(-8.1%) | -$96.90M(+4.0%) |
| Mar 2017 | - | -$27.24M(+22.6%) | -$93.18M(+13.8%) |
| Dec 2016 | -$81.88M(+202.9%) | -$22.21M(-0.9%) | -$81.88M(+51.5%) |
| Sep 2016 | - | -$22.41M(+5.1%) | -$54.05M(-1.4%) |
| Jun 2016 | - | -$21.33M(+33.8%) | -$54.80M(+87.9%) |
| Mar 2016 | - | -$15.94M(-383.6%) | -$29.16M(+7.9%) |
| Dec 2015 | -$27.03M(-57.0%) | $5.62M(-124.3%) | -$27.03M(-26.0%) |
| Sep 2015 | - | -$23.16M(-636.3%) | -$36.55M(+13.2%) |
| Jun 2015 | - | $4.32M(-131.3%) | -$32.29M(-37.2%) |
| Mar 2015 | - | -$13.81M(+254.4%) | -$51.43M(-18.1%) |
| Dec 2014 | -$62.79M(-21.7%) | -$3.90M(-79.4%) | -$62.79M(-21.7%) |
| Sep 2014 | - | -$18.90M(+27.5%) | -$80.16M(+0.6%) |
| Jun 2014 | - | -$14.82M(-41.1%) | -$79.70M(-8.3%) |
| Mar 2014 | - | -$25.17M(+18.4%) | -$86.94M(+8.4%) |
| Dec 2013 | -$80.20M | -$21.26M(+15.3%) | -$80.20M(+26.6%) |
| Sep 2013 | - | -$18.44M(-16.4%) | -$63.35M(-2.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$22.06M(+19.6%) | -$64.91M(+14.1%) |
| Mar 2013 | - | -$18.44M(+318.5%) | -$56.87M(+6.2%) |
| Dec 2012 | -$53.55M(+170.9%) | -$4.41M(-78.0%) | -$53.55M(-20.7%) |
| Sep 2012 | - | -$20.01M(+42.7%) | -$67.51M(+59.4%) |
| Jun 2012 | - | -$14.02M(-7.3%) | -$42.35M(+67.8%) |
| Mar 2012 | - | -$15.12M(-17.6%) | -$25.23M(+27.6%) |
| Dec 2011 | -$19.77M(-63.6%) | -$18.36M(-456.3%) | -$19.77M(+2.5%) |
| Sep 2011 | - | $5.15M(+66.4%) | -$19.29M(-47.7%) |
| Jun 2011 | - | $3.10M(-132.0%) | -$36.88M(-29.3%) |
| Mar 2011 | - | -$9.66M(-46.0%) | -$52.13M(-3.9%) |
| Dec 2010 | -$54.26M(-7.2%) | -$17.88M(+43.8%) | -$54.26M(+10.6%) |
| Sep 2010 | - | -$12.43M(+2.3%) | -$49.05M(-3.0%) |
| Jun 2010 | - | -$12.15M(+3.1%) | -$50.56M(-8.9%) |
| Mar 2010 | - | -$11.79M(-7.0%) | -$55.49M(-5.1%) |
| Dec 2009 | -$58.46M(+15.9%) | -$12.68M(-9.1%) | -$58.46M(-6.9%) |
| Sep 2009 | - | -$13.94M(-18.4%) | -$62.81M(+4.6%) |
| Jun 2009 | - | -$17.08M(+15.8%) | -$60.07M(+10.5%) |
| Mar 2009 | - | -$14.76M(-13.3%) | -$54.36M(+7.8%) |
| Dec 2008 | -$50.43M(+79.2%) | -$17.03M(+52.0%) | -$50.43M(+16.4%) |
| Sep 2008 | - | -$11.20M(-1.5%) | -$43.34M(+7.1%) |
| Jun 2008 | - | -$11.37M(+5.0%) | -$40.45M(+15.9%) |
| Mar 2008 | - | -$10.83M(+9.1%) | -$34.90M(+24.0%) |
| Dec 2007 | -$28.15M(+80.6%) | -$9.93M(+19.5%) | -$28.15M(+23.0%) |
| Sep 2007 | - | -$8.31M(+42.5%) | -$22.89M(+24.4%) |
| Jun 2007 | - | -$5.83M(+42.9%) | -$18.41M(+15.1%) |
| Mar 2007 | - | -$4.08M(-12.6%) | -$15.99M(+2.6%) |
| Dec 2006 | -$15.58M(+14.9%) | -$4.67M(+22.0%) | -$15.58M(+7.5%) |
| Sep 2006 | - | -$3.83M(+12.0%) | -$14.49M(+0.4%) |
| Jun 2006 | - | -$3.42M(-7.0%) | -$14.43M(+3.4%) |
| Mar 2006 | - | -$3.67M(+2.6%) | -$13.96M(+3.0%) |
| Dec 2005 | -$13.56M(+49.2%) | -$3.58M(-5.0%) | -$13.56M(+8.4%) |
| Sep 2005 | - | -$3.77M(+27.8%) | -$12.51M(+4.2%) |
| Jun 2005 | - | -$2.95M(-9.9%) | -$12.01M(+7.7%) |
| Mar 2005 | - | -$3.27M(+29.4%) | -$11.15M(+22.7%) |
| Dec 2004 | -$9.09M(<-9900.0%) | -$2.53M(-22.5%) | -$9.09M(+64.4%) |
| Sep 2004 | - | -$3.26M(+56.2%) | -$5.53M(+106.8%) |
| Jun 2004 | - | -$2.09M(+73.0%) | -$2.67M(+179.5%) |
| Mar 2004 | - | -$1.21M(-217.0%) | -$956.20K(<-9900.0%) |
| Dec 2003 | $0.00(0.0%) | $1.03M(-352.9%) | $0.00(-100.0%) |
| Sep 2003 | - | -$408.20K(+9.5%) | -$1.01M(+64.0%) |
| Jun 2003 | - | -$372.90K(+48.3%) | -$618.40K(+134.4%) |
| Mar 2003 | - | -$251.40K(-1458.9%) | -$263.80K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $18.50K(-246.8%) | $0.00(-100.0%) |
| Sep 2002 | - | -$12.60K(-31.1%) | -$18.50K(+213.6%) |
| Jun 2002 | - | -$18.30K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40K | $12.40K |
| Dec 2001 | -$39.70K | - | - |
FAQ
- What is Halozyme Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual EBIT year-on-year change?
- What is Halozyme Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly EBIT year-on-year change?
- What is Halozyme Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM EBIT year-on-year change?
What is Halozyme Therapeutics annual earnings before interest & taxes?
The current annual EBIT of HALO is $575.23M
What is the all time high annual EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual earnings before interest & taxes is $575.23M
What is Halozyme Therapeutics annual EBIT year-on-year change?
Over the past year, HALO annual earnings before interest & taxes has changed by +$208.14M (+56.70%)
What is Halozyme Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of HALO is $148.35M
What is the all time high quarterly EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly earnings before interest & taxes is $182.75M
What is Halozyme Therapeutics quarterly EBIT year-on-year change?
Over the past year, HALO quarterly earnings before interest & taxes has changed by +$47.82M (+47.56%)
What is Halozyme Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of HALO is $623.04M
What is the all time high TTM EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM earnings before interest & taxes is $623.04M
What is Halozyme Therapeutics TTM EBIT year-on-year change?
Over the past year, HALO TTM earnings before interest & taxes has changed by +$212.20M (+51.65%)